Topics / Hematology
Weekly issue
Hematology Papers of the Week
The top Hematology papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.
- 1Salidroside Regulates Blood-brain Barrier Integrity Via Lcn2-NLRP3 Signaling Axis Inhibition for High-altitude Hypoxic Brain Injury Intervention
A low-pressure oxygen chamber was used to simulate high-altitude environments to establish the mouse HHBI model.
- 2
- 3CD19-CD28 Costimulatory Bispecific Antibody Plus Glofitamab in R/R B-NHL: A Phase 1 Dose-escalation Study
In this study, 52 patients with heavily pre-treated B-NHL (aggressive, n = 33; indolent, n = 19) received obinutuzumab pretreatment to mitigate cytokine release syndrome, glofitamab step-up dosing (2.5/10/30 mg), and the addition of CD19-CD28 (initiated on cycle 1 day 10 or cycle 2 day 8), for up to 12 cycles.
- 4Tumor Cells Hijack Coagulation Signaling to Enable Immune Escape and Metastatic Dissemination
Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC).
- 5CD3scFv-Engineered AAV Capsid Drives Superior In Vitro and In Vivo CAR-T Cell Generation and Leads to Complete Eradication of CD19+ Tumors
In vivo, a single intravenous dose of AVO-100 at 2×10 vector genomes (vg) per subject using NSG mice bearing Raji xenografts, prompted complete tumor eradication and significantly prolonged survival, whereas control untreated animals succumbed to a progressive disease. These results demonstrate that site-selective CD3scFv insertion into a single AAV capsid protein provides a robust, versatile platform for improved T cell transduction and effective in vivo CAR-T cell generation, offering a promising off-the-shelf approach for treating B cell malignancies.
Get papers like these the day they come out, not a week later.
Follow this category- 6Risk-Adapted Donor Selection in Patients with Acute Myeloid Leukemia
We applied a doubly robust strategy combining multinomial propensity-score inverse probability of treatment weighting (IPTW) with multivariable Cox and Fine-Gray regression.
- 7
- 8Cas12a-based Combinatorial Knockout Screens Define The Genetic Architecture of The DNA Damage Response
To elucidate the genetic architecture of the DNA damage response (DDR) network, we conduct unbiased genetic interaction screens using Cas12a.
- 9Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
We analyzed 11 340 patients and identified 418 BCOR/L1-mutated patients, focusing on differences between MN and BMF.
- 10Environmental Risk Factors for Acute Myeloid Leukemia in Adults, A Systematic Review
In a systematic review, we aimed to investigate the existing evidence.
- 11Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for The Duffy Null Population
We aimed to verify the adult Duffy null ANC RI and develop WBC and ANC RIs for pediatrics.
- 12
- 13Final Analysis of The BRUIN Phase 1/2 Study Assessing The Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL
Here, we report final results from the global Phase 1/2 BRUIN trial evaluating pirtobrutinib in patients with R/R MCL, with and without prior cBTKi exposure.
- 14
- 15Terminal Differentiation Program of CD8 T Cells Guides Immunotherapeutic Options for CLL Patients
Here, we performed an integrated phenotypic, epigenetic and functional analysis of circulating CD8⁺ T cells from treatment-naive CLL patients to define the nature and therapeutic relevance of terminal differentiation in CLL.
- 16Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of The BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials
To better characterize the therapeutic benefits of the addition of carboplatin to anthracycline- and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC), we performed a pooled analysis of three randomized clinical trials: BrighTNess (NCT02032277), CALGB 40603 (NCT00861705), and GeparSixto (NCT01426880).
- 17Antigen Scaffolds Drive Preferential Expansion of Functional Genetically Engineered CAR and TCR T Cells
However, manufacturing is resource intensive and often yields highly differentiated, exhausted T cell products. To address this, we developed an antigen-scaffold (Ag-scaffold) technology that presents cognate antigen alongside stimulatory cytokines to preferentially expand genetically engineered T cells.
- 18Associations Between Biomarkers of Vitamin K and Cardiovascular Disease Risk Factors: The Role of Lipids
We investigated the associations between levels of circulating vitamin K vitamers, phylloquinone (PK) and total menaquinones (MK), and dephospho-undercarboxylated matrix Gla protein (dp-ucMGP, a biomarker of functional vitamin K status), with multiple cardiovascular disease risk factors and adjusted for triglycerides.
- 19Impact of Venetoclax-based Therapies on CLL-associated Autoimmune Cytopenias: A Retrospective Study Conducted By ERIC
This study aimed to evaluate preexisting and treatment-emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax-based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti-CD20 monoclonal antibodies and/or BTK inhibitors).
- 20Monoclonal Gammopathy of Neurologic Significance: A Practical Framework for Diagnosis and Management
This review presents a practical, stepwise diagnostic and therapeutic framework for MGNS, emphasizing multidisciplinary collaboration between hematology and neurology.